Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The total therapy (TT) IIIB phase 2 study incorporated bortezomib into tandem melphalan–based hematopoietic stem cell transplantation with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide for induction/consolidation and bortezomib, lenalidomide, and dexamethasone (VRD) for maintenance in patients with newly diagnosed multiple myeloma (MM). This updated analysis presents a 15.4-year median follow-up. Of 177 patients, 21% patients had gene expression profile (GEP)–defined high-risk MM. 15-year progression free survival (PFS) was 27.9%. Median PFS was better in GEP–defined low-risk patients at 7.8 years and in International Staging System stage 1 patients at 8.7 years. Overall, median OS was 9.1 years, and 15-year overall survival (OS) was 35.9%. GEP–defined low-risk patients’ median OS was 11.2 years, and that of GEP–defined high-risk patients was 2.8 years. There was no difference in OS between TT IIIB and TT IIIA. This study includes the longest follow-up of patients treated with maintenance VRD reported to date. In patients with GEP–defined low-risk, nearly half and one-third of patients without ongoing treatment showed no signs of progression at 10 and 15 years, respectively. One-third of patients survived more than 15 years, but 3 years of VRD maintenance did not improve outcomes for patients with GEP–defined high-risk MM.

Cite

CITATION STYLE

APA

Al Hadidi, S., Ababneh, O. E., Schinke, C. D., Thanendrarajan, S., Bailey, C., Smith, R., … van Rhee, F. (2024). Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Advances, 8(3), 703–707. https://doi.org/10.1182/bloodadvances.2023011601

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free